<p>Oligomerix has appointed Dr. Cara Cassino as interim president and chief executive officer as the privately held biotech moves from discovery toward clinical development of its lead Alzheimer’s candidate. Cassino has served on the Oligomerix board since July 2025 and brings about 25 years of clinica</p>